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Abstract: RNA processing is a tightly regulated and highly complex pathway which 
includes transcription, splicing, editing, transportation, translation and degradation. It has 
been well-documented that splicing of RNA polymerase II medicated nascent transcripts 
occurs co-transcriptionally and is functionally coupled to other RNA processing. Recently, 
increasing experimental evidence indicated that pre-mRNA splicing influences RNA 
degradation and vice versa. In this review, we summarized the recent findings demonstrating 
the coupling of these two processes. In addition, we highlighted the importance of splicing 
in the production of intronic miRNA and circular RNAs, and hence the discovery of the 
novel mechanisms in the regulation of gene expression. 
Keywords: pre-mRNA splicing; RNA surveillance; exosome; microRNA processing; 
mirtron; circular RNA 
 
1. Introduction 
Most eukaryotic protein-coding genes contain introns. Human primary pre-mRNAs on average 
contain approximately 27 K nucleotides and 9 exons, but an average mature mRNA contains only 3.5 K 
nucleotides [1]. In other words, more than 85% of the nucleotides are intronic sequences which should 
be removed before the mRNA is being translated. The reason why cells waste so many resources to 
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generate the “junk” during transcription remains a mystery. However, undoubtably, an effective system 
to recognize and remove introns is essential for preventing the production of abnormal proteins, which 
may function in a dominant negative manner and competitively inhibit the activity of their full-length 
native form [2]. 
Pre-mRNA splicing is a succession of two transesterification reactions (Figure 1). The reactions are 
catalyzed by the complex named spliceosome. Spliceosome is a complex comprised of both RNA 
molecules (e.g., small nuclear ribonucleoproteins) and proteins. Spliceosome is found throughout  
the entire nucleus [3], where transcription and many other RNA processing pathways take place. 
Spliceosome recognizes a donor splice site and an acceptor splice site that are located at the 5' and 3' end 
of intron, respectively. For the 5' splice site, the only highly conserved cis-elements are the proximal 
dinucleotide (GU) of the intron. However, for the 3' splice site, three separated cis-elements are required: 
the branch site, the polypyrimidine tract and the 3' splice site dinucleotide (AG). In brief, for the first 
trans-esterification reaction, the 2' hydroxyl group of the conserved adenosine at the branch site attacks 
the conserved guanine of the 5' splice site at the exon-intron junction. A 2'–5' phosphodiester bond is formed 
and the exon-intron junction is cleaved. A 2'–5' phosphodiester RNA lariat structure and a free 3'-OH 
(leaving group) at the upstream exon are produced. After the rearrangement of the spliceosome 
components, the second trans-esterification reaction begins with another nucleophilic attack. The 3'-OH 
end of the released exon attacks the scissile phosphodiester bond of the conserved guanine of the 3' splice 
site at the intron-exon junction. Finally, the two exons are ligated together and the intron is released as 
a stable lariat structure product [4]. The lariats need to be debranched by debranching enzymes before 
degraded or processed into useful RNAs such as intronic snoRNAs and mirtrons [4]. Intronic lariats will 
accumulate in the cytoplasm in the absence of Dbr1 enzymatic activity [5]. 
 
Figure 1. Pre-mRNA splicing includes intron exclusion and exon ligation. In most cases, 
introns start from the sequence GU as 5' splice sites and end with the sequence AG as  
3' splice site. A highly conserved nucleotide A at the branch site located approximately  
20–50 bases upstream of the 3' splice site. Lariat was considered as an unstable intermediate. 
Recent findings suggested that those intron products have unexpected long half-lives and are 
precursors for other RNAs such as miRNAs from mirtrons [6]. The factors determining the 
stability and fate of intron products are largely unknown. 
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In addition to the 5' and 3' splice sites mentioned above, additional cis-elements named 
exonic/intronic splice enhancers or silencers can also influence the overall fidelity of pre-mRNA  
splicing [7–9]. An analysis focusing on mutations near splice junctions revealed that approximately 15% 
of disease causing mutations lead to RNA splicing defects [10,11]. With the advent of advanced strategies 
for predicting the effects of sequence variations on splicing and cryptic splice sites, more diseases caused 
by splicing defects will be explored [12–14]. Defects in pre-mRNA splicing are considered as the 
primary cause of many diseases, such as neurodegenerative diseases and cancers [15–20]. Hence, 
targeting pre-mRNA splicing could be a potential treatment for those diseases [5,21–25]. 
On the other hand, pre-mRNA splicing requires some degree of flexibility [26]. Exons and  
introns are either retained or removed to generate a diversity of splicing variants known as alternative 
splicing [27,28]. Alternative splicing is essential for regulation of gene expression and for increasing the 
proteome complexity. For example, a premature stop codon is introduced by alternative splicing that 
suppresses the expression of the gene by degradation through nonsense-mediated decay (NMD) during 
cytoplasmic translation [29]. In addition, alternatively spliced mRNA variants can produce protein 
isoforms with altered amino acid sequences and domains resulting in changes in enzymatic activity, 
cellular localization and/or binding partners [1]. Therefore, alternative splicing is considered to be the 
most important source of structural and functional diversity at the protein level. It is estimated that about 
95% of transcripts from multi-exon genes undergo alternative splicing, some instances of which occur 
in a tissue-specific manner and/or under specific cellular conditions [30,31]. There are four main types 
of alternative splicing events (Figure 2), including exon skipping, intron retention, alternative 3' splice 
site and 5' splice site selection [27]. More complex alternative splicing events such as mutually exclusive 
exons, exon/intron scrambling, alternative promoter usage and alternative polyadenylation are less 
frequent [27,32]. 
 
Figure 2. Many splicing variants could be formed from the same pre-mRNA by alternative 
splicing. Circular RNA, generated by splicing, is a new member of the splicing variants. 
Several mechanisms for the formation of circular RNAs have been proposed, including the 
circularization of exons, facilitated by the presence of adjacent repetitive sequence [33–36]. 
Although splicing is tightly regulated [37–40], several lines of evidence suggested that the  
splicing of many pre-mRNAs is suboptimal [41] and that unspliced nascent transcripts and aberrant 
splicing intermediates are detected, especially when the intracellular RNA degradation activities are 
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inhibited [42–48]. The recognition and degradation of the unspliced/mis-spliced transcripts and the 
excised introns become very crucial steps to maintain proper cellular growth and even survival. In this 
review, we summarized recent findings in coupling and coordination in gene expression processes with  
pre-mRNA splicing. The “by-products” generated from splicing escaped from RNA degradation were 
also discussed. 
2. Splicing and Nuclear RNA Surveillance 
So far, most studies are focusing on the recognition and degradation of unspliced mRNA by  
nonsense-mediated mRNA decay (NMD) [49–51]. NMD is an important RNA surveillance system that 
functions to detect and degrade RNAs with premature stop codon and prevent the expression of 
erroneous or truncated proteins in cytoplasm. A typical branchpoint usually harbors a translation 
termination codon without proper splicing. It remains at the unspliced RNAs and triggers the activity of 
NMD [46]. Therefore, the stop codon within splicing signal provides an important role to guarantee the 
cytoplasmic degradation of unspliced transcripts by NMD. 
Nevertheless, a number of observations bring to the idea that nuclear RNA surveillance system not 
only plays a key role in eliminating the aberrant unspliced transcripts and splicing intermediates, but 
also directly involves in the regulation of the splicing process. Firstly, most of the unspliced mRNAs are 
trapped in the nucleus [52,53]. Secondly, unspliced transcripts and splicing intermediates are hardly 
detected in wild-type cells unless nuclear RNA surveillance is inactivated [42–44]. Thirdly, certain 
nuclear exosome components are recruited to intronic regions of transcribing genes [54–56]. Fourthly, 
a number of RNA binding factors, such as shuttling Ser-Arg-rich (SR) RNA-binding proteins and cap 
binding complex (CBC), which are recruited cotranscriptionally and exhibit physical or genetic 
interactions with nuclear RNA surveillance components, are directly involved in splicing [57–63]. 
Finally, splice-site mutations can cause Rrp6p-mediated nuclear retention of the unspliced RNAs and 
transcriptional down-regulation of the splicing-defective genes [43,64]. 
The exosome is a multi-subunit protein complex involved in RNA surveillance by degrading 
aberrantly processed RNAs and RNA processing intermediates [65]. Both nuclear and cytoplasmic 
exosomes have the same common core components, but are decorated with a variety of different 
peripheral proteins (such as Rrp6p, Dis3p, TRAMP and SKI complex) [66]. According to the current 
model, substrates of the nuclear exosome are recognized and subsequently recruited to the nuclear 
exosome by its cofactor, TRAMP complex [67–69]. The TRAMP complex is also a multi-protein 
complex comprising of the RNA helicase Mtr4p, a poly(A) polymerase (either Trf4p or Trf5p) and a 
zinc knuckle RNA binding protein (either Air1p or Air2p) [70]. The TRAMP complex cooperates with 
the nuclear exosome of eukaryotic cells and is involved in the 3' end processing of snoRNAs and 
ribosomal RNA. TRAMP complex is cotranscriptionally recruited to nascent RNA transcript [71], and 
physically interacts with spliced-out introns [72] and splicing factors [71,73], and thereby facilitates their 
degradation by the exosome. Deletion of TRAMP components leads to further accumulation of unspliced 
pre-mRNAs even in a yeast strain defective in nuclear exosome activity, suggesting a novel stimulatory 
role of TRAMP in splicing [71]. The cotranscriptional recruitment of TRAMP before or during splicing 
may function as a fail-safe mechanism to ensure the preparation for the subsequent targeting of spliced-
out introns for rapid degradation by the nuclear exosome [71,73]. 
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Consistent with the hypothesis above, recent study demonstrated that two shuttling SR proteins 
Gbp2p and Hrb1p are necessary for quality control of spliced mRNAs [74]. Gbp2p and Hrb1p stabilize 
the binding between TRAMP complex and spliceosome-bound transcripts [74]. Unspliced RNAs are 
retained in the nucleus and channeled to the TRAMP/exosome mediated degradation by Gbp2p and 
Hrb1p [74]. Taken together, Gbp2p and Hrb1p function as part of the fail-safe mechanism to ensure  
the cotranscriptional recruitment of TRAMP before or during splicing to prepare for the subsequent 
targeting of spliced-out introns to rapid degradation by the nuclear exosome. However, it remains unclear 
when the nuclear exosome and TRAMP are recruited and how they recognize unspliced pre-RNAs or 
spliced introns. 
3. Spliceosome-Mediated Decay 
Spliceosome-mediated decay (SMD) was first proposed in 2013 when it was observed that the 
expression of ~1% of mRNAs without any intron were upregulated in the yeast cells defective with the 
splicing factor PRP40 [75]. Spliceosome associates with those intronless mRNAs probably through the 
cis-elements similar to 5' splice site and branchpoint splice signals (Figure 3). The spliceosome 
endonucleolytically cleaves those intronless mRNA and the products are degraded by a nuclear RNA 
surveillance system [75]. The existence of SMD provided a plausible explanation for the coordinated 
regulation of expression levels of the homologous genes bromodomain factor (BDF) 1 and BDF2 in the 
yeast under different stress conditions [76]. Interestingly, the expression level of BDF2 is also subjected 
to an additional layer of post-transcriptional control through RNase III-mediated decay (RMD) [77]. 
RNase III Rnt1p cleaves a stem-loop structure within the BDF2 mRNA to down-regulate its  
expression [77]. The SMD and RMD pathways of the BDF2 mRNA are differentially activated or 
repressed in specific environmental conditions [77]. The crosstalk between SMD and RMD pathways 
remain to be further explored. 
 
Figure 3. Many intronless mRNAs contain splice signals similar to 5' splice site and branch 
point. Spliceosome are recruited by the splice signals and catalyzes the first transesterification. 
Maybe due to lack of proper 3' splice site required for the canonical pre-mRNA splicing as 
shown in Figure 1, spliceosome only cleaves the intronless mRNA at the 5' splice site without 
proceeding to the second transesterification. The incompletely spliced products are degraded 
by the nuclear exosome. Ineffective transition from the first to the second step of splicing 
could also promote the pre-mRNA to nuclear degradation [75]. 
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4. Splicing and microRNA Processing 
miRNAs are categorized as “intergenic” or “intronic” by their genomic locations. Large-scale 
bioinformatic analysis identified that many pre-microRNAs (miRNAs) are located in introns (named 
mirtrons) [78–80] or across exon-intron junctions [81]. As intronic miRNAs share common regulatory 
mechanisms with their host genes, the expression patterns of intronic miRNAs and their host genes are 
similar, while intergenic miRNAs are known to be transcribed as independent transcription units [82]. 
As shown in Figure 4, coupling between the splicing and microRNA processing machineries within a 
supraspliceosome context was proposed [83–86]. Supraspliceosome is a huge (21 MDa) nuclear 
ribonucleoprotein (RNP) complex in which numerous pre-mRNA processing steps take place [87]. Two 
key components of microRNA processing (the ribonuclease (RNase) III enzyme Drosha and the RNA 
binding protein DGCR8) and pre-miRNAs are co-sedimented with supraspliceosomes by glycerol 
gradient fractionation [85]. Other splicing factors such as serine/arginine-rich splicing factor 1 (SRSF1; 
Formerly SF2/ASF), heterogeneous nuclear ribonucleoprotein (hnRNP) A1 and K homology (KH) 
domain RNA binding protein (KSRP) have been proposed with moonlighting function in microRNA 
processing [88–91]. Processed pri-miRNAs are also found in supraspliceosomes [87]. Recent findings 
supported the model that the initiation of spliceosome assembly at the 5' splice site promotes microRNA 
processing by recruiting Drosha to intronic miRNAs [92]. Knockdown of U1 splicing factors globally 
reduces intronic miRNAs. It is consistent with the notion that the first step of the processing of mirtrons 
is splicing instead of microRNA processing and the debranched introns mimic the structural features of 
pre-miRNAs to enter the miRNA-processing pathway without Drosha-mediated cleavage [93]. 
Interestingly, Drosha may function as a splicing enhancer and promote exon inclusion [94]. Drosha binds 
to the exon and stimulates splicing in a cleavage-independent but structure-dependent manner [94]. To 
sum up, the expression of mirtrons is positively regulated by the splicing and microRNA processing. 
 
Figure 4. Left panel, according to the current model of mirtronic microRNAs biogenesis, 
spliced mirtronic lariat was first linearized by the debranching enzyme (Dbr) and then 
cleaved by Drosha; Right panel, recent studies suggested that splicing and microRNA 
processing are more closely associated than previously thought. Drosha is recruited to splice 
site with spliceosome as supraspliceosome [84,85]. Drosha may play a key role in the 
coordination of the regulation of mirtronic microRNAs biogenesis and splicing. 
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Interestingly, some intronic miRNAs in humans can be transcribed independently of their host genes. 
The competition model between spliceosome and microRNA processing complex was proposed 
especially for miRNAs across exon-intron junctions [81,95]. It was suggested that nearby cis-elements 
and pre-miRNA secondary structure would interfere with splice site recognition [81,95]. In addition, 
inhibition of splicing by spliceostatin A upregulates the levels of the intronic miRNAs [85], whereas 
overexpression of Drosha increases the levels of the intronic and the exonic miRNAs [81]. These 
findings strongly supported that Drosha, instead of the miRNAs generated from canonical miRNA gene 
silencing pathway, directly represses the expression of genes by cleavage of the mRNAs [81]. 
5. Splicing and Circular RNAs 
Circular RNAs are widely expressed noncoding RNAs and are generated cotranscriptionally by  
non-canonical mode of RNA splicing [32,83,96,97]. As mentioned above, during splicing,  
the spliceosome produces a free OH group at the 3' end of the intron. This free OH group attacks the 
phosphodiester bond between the downstream exon and intron. A debranching failure and “back-splicing” 
(a process in which downstream exons are spliced to upstream exons in reverse order [33,83,98–100]) 
produces a circular intronic long non-coding RNAs [101]. Recent deep sequencing studies have clearly 
revealed that thousands of circular RNAs generated from protein-coding genes in many organisms 
including human, and the number of circular RNAs per cell is far more than their linear protein-coding 
RNAs counterparts [83,102–107]. The accumulation of circular RNAs in cells may be attributed to the higher 
resistance of circular RNAs to endogenous exoribonucleases and hence their longer half-life [100,107,108]. 
Although circular RNAs are produced during splicing, the production of circular RNAs competes 
with canonical pre-mRNA splicing was also observed [96]. The production of these circular RNAs is 
mediated by intronic sequences [96,102,103,109]. A recent study demonstrated that the expression of a 
subset of circular RNA is regulated by the splicing factor muscleblind [96]. Therefore, circular RNAs 
may not only represent products of defective pre-mRNA splicing and nuclear RNA surveillance. They 
may actually be actively produced [34]. Interestingly, the production of circular RNAs seems to be 
responsible for a decline in the efficiency of canonical linear splicing. Circular RNAs accumulate in the 
nervous system and increase with age in Drosophila [110]. The mechanism and function of age-related 
modulation of circular RNA accumulation remain to be explored. 
The function of most circular RNAs remains unclear, although their expression levels are closely 
related to diseases [105,111]. As circular RNAs are mainly found in the nucleus rather than the 
cytoplasm [103], and circular RNAs lack proper start and/or stop codons, it is unlikely that circular 
RNAs can code for proteins. However, a number of mechanisms of the regulatory potency of circular 
RNAs in gene expression are proposed. Certain circular RNAs function in regulating the expression of 
their host genes [103]. Circular RNAs accumulate at their sites of transcription, associate with elongation 
RNA polymerase II (RNAP II), and acts as a positive regulator of RNAP II transcription [103]. Some of 
these circular RNAs have been shown to act as molecular sponges by competing and/or sequestering 
miRNAs, and hence regulates miRNA level [112]. The potential function of circular RNAs in gene 
expression, their association with diseases in humans and their implications for therapeutic applications 
remains to be further explored [34,113]. 
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6. Conclusions and Perspectives 
In summary, the interactions between splicing and other RNA processing systems are more 
complicated and dynamic than we have ever thought. How does the exosome distinguish its targets 
splicing intermediates from the fully spliced RNAs? How is the expression of the selected splicing 
variants, intronic miRNAs and circular RNAs regulated through the coordination of the pre-RNA 
splicing and other RNA processing pathways? Those fundamental questions remain unaddressed. 
Through advances in technologies [114–116], development of new strategies [117–123], and 
establishment of databases for sharing information [124–126], hopefully those questions will be 
addressed in the near future. 
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